- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05706831
Muziekinterventie en transcraniële elektrische stimulatie voor neurologische aandoeningen
Muziekinterventie en transcraniële elektrische stimulatie voor de behandeling van neurologische aandoeningen
The goal of this clinical trial is to evaluate the efficacy of a musical interventionand non-invasive brain stimulation in neurological patients. The main questions it aims to answer are:
- to evaluate the residual neuroplastic processes in DOC state related to music exposure
- to determine the putative modulation of the aforementioned processes and the clinical outcome of DOC patients by non-pharmacological strategies, i.e., electric (tDCS) and music stimulation
- to evaluate the impact of this intervention on caregiver's burden and psychological distress.
Participants will be randomly assigned to one of three different music-listening intervention groups. Primary outcomes will be clinical, that is based on the neurologist's observations of clinical improvement, and neurophysiological, collected pre-intervention, post-intervention and post-placebo.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Simona Spaccavento
- Telefoonnummer: +393332783524
- E-mail: simona.spaccavento@icsmaugeri.it
Studie Locaties
-
-
Ba
-
Bari, Ba, Italië, 70025
- Werving
- Istituti Clinici Scientifici Maugeri
-
Contact:
- Simona Spaccavento
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age > 18 years
- Post-stroke aphasia
- Post-stroke neglect
- Patients with disorders of consciusness (DOC)
Exclusion Criteria:
- No auditory injury
- no hystory of neurological disease
- No hystory of psychiatric disease
- Previous stroke
- use of alcohol and drugs
- premorbid dementia
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Group 1
Group 1 will receive tEs combined with music stimulation for 2 weeks, 1 week of wash out, then sham stimulation combined with noise (placebo) for other 2 weeks. |
music |
|
Experimenteel: Group 2
Group 2 will receive sham stimulation and noise (placebo) for the first 2 weeks, then 1 week wash out, and finally tEs and music stimulation for other 2 weeks. |
music |
|
Experimenteel: Group 3
Group 3 will receive only music stimulation and sham stimulation for 2 weeks, 1 week of wash out, then sham stimulation and noise (placebo) for another 2 weeks. |
music |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Coma Recovery Scale- Revised at 2 weeks and 4 weeks
|
-Coma Recovery Scale-Revised (CRS-R) - (0-23). High score means a better outcome. |
Change from baseline Coma Recovery Scale- Revised at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Disability Rating Scale at 2 weeks and 4 weeks
|
Disability Rating Scale (DRS) - (0-29). High score means a worse outcome. |
Change from baseline Disability Rating Scale at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Rancho Levels of Cognitive Functioning at 2 weeks and 4 weeks
|
Rancho Levels of Cognitive Functioning (LCF) - (1-8). High score means a better outcome. |
Change from baseline Rancho Levels of Cognitive Functioning at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Glasgow Outcome Scale- Extended at 2 weeks and 4 weeks
|
Glasgow Outcome Scale- Extended (GOS-E) - (1-8). High score means a better outcome. |
Change from baseline Glasgow Outcome Scale- Extended at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Aachener Aphasie Test at 2 weeks and 4 weeks
|
Aachener Aphasie Test (AAT). This test includes six subtests: spontaneous speech, token test, repetition, written language, naming, and comprehension. Spontaneous speech is structured in six parts (0-30). High score means a better performance; Token test is composed by 50 items; for the score the number of error id considered (0-50). Repetition sub test is composed by 50 items; for each item the score range from 0 to 3; high score means better outcome (0-150). Written language subtest is composed by 30 items; for each item the score range from 0 to 3; high score means better outcome (0-90). Naming subtest is composed by 40 items; for each item the score range from 0 to 3; high score means better outcome (0-120). Comprehension subtest is composed by 40 items; for each item the score range from 0 to 3; high score means better outcome (0-120). |
Change from baseline Aachener Aphasie Test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Italian version of Functional Outcome Questionnaire for Aphasie at 2 weeks and 4 weeks
|
Italian version of Functional Outcome Questionnaire for Aphasie (FOQ-A) - (32-160). High score means a better outcome. |
Change from baseline Italian version of Functional Outcome Questionnaire for Aphasie at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Functional Assessment Measure - Cognitive subscale at 2 weeks and 4 weeks
|
Functional Assessment Measure - Cognitive subscale - (FAM) - (14-98); high score means a better outcome. |
Change from baseline Functional Assessment Measure - Cognitive subscale at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Quality of Life Questionnaire for aphasics at 2 weeks and 4 weeks
|
Quality of Life questionnaire for Aphasics (QLQA) - (0-148); High score means a better outcome. |
Change from baseline Quality of Life Questionnaire for aphasics at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline The semi-structured scale for functional evaluation of personal neglect at 2 weeks and 4 weeks
|
The semi-structured scale for functional evaluation of personal neglect - (0-9); High score means a worse outcome. |
Change from baseline The semi-structured scale for functional evaluation of personal neglect at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Barrage Test at 2 weeks and 4 weeks
|
Barrage test (0-36). High score means a better outcome. |
Change from baseline Barrage Test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Letter cancellation test at 2 weeks and 4 weeks
|
Letter cancellation test - (0-104). High score means a better outcome. |
Change from baseline Letter cancellation test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Sentence reading test at 2 weeks and 4 weeks
|
Sentence reading test (0-6). High score means a worse outcome. |
Change from baseline Sentence reading test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline Wundt-Jastrow area illusion test at 2 weeks and 4 weeks
|
Wundt-Jastrow area illusion test (0-20). High score means a worse outcome. |
Change from baseline Wundt-Jastrow area illusion test at 2 weeks and 4 weeks
|
|
Neuropsychological outcomes
Tijdsspanne: Change from baseline The semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks and 4 weeks
|
The semi structured scale for the functional evaluation of extrapersonal neglect (0-9). High score means a worse outcome. |
Change from baseline The semi structured scale for the functional evaluation of extrapersonal neglect at 2 weeks and 4 weeks
|
|
Neurophysiological outcome
Tijdsspanne: Change from baseline oscillation at 2 weeks and 4 weeks
|
The ratio of fast (8-30 Hz, α-β) to slow (2-8 Hz, δ-θ) oscillation amplitude at the midline electrodes (Fz, Cz, Pz, Oz) will be measured and compared pre- and post intervention." |
Change from baseline oscillation at 2 weeks and 4 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Caregiver psychological distress
Tijdsspanne: Change from baseline Back depression Inventory II at 2 weeks and 4 weeks
|
Back depression Inventory II (BDI II) - (0-63). High score means a worse outcome. |
Change from baseline Back depression Inventory II at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Tijdsspanne: Change from baseline State-trait anxiety inventory; at 2 weeks and 4 weeks
|
State-trait anxiety inventory (STAI-Y). It is composed by two scales: STAI-Y State (20-80) and STAI-Y Trait (20-80). High score means a worse outcome. |
Change from baseline State-trait anxiety inventory; at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Tijdsspanne: Change from baseline Questionario psicofisiologico (CBA) at 2 weeks and 4 weeks
|
Psychophysiological Questionnaire (30-120). WHOQOL-BREF. |
Change from baseline Questionario psicofisiologico (CBA) at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Tijdsspanne: Change from baseline Prolonged grief disorder -12 at 2 weeks and 4 weeks
|
Prolonged grief disorder -12 (PG-12) - (11-55). High score means a worse outcome. |
Change from baseline Prolonged grief disorder -12 at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Tijdsspanne: Change from baseline Family strain questionnaire at 2 weeks and 4 weeks
|
Family strain questionnaire (FSQ) - (1-44). High score means a worse outcome. |
Change from baseline Family strain questionnaire at 2 weeks and 4 weeks
|
|
Caregiver psychological distress
Tijdsspanne: Change from baseline Wolrd health organization - quality of life at 2 weeks and 4 weeks
|
better outcome. |
Change from baseline Wolrd health organization - quality of life at 2 weeks and 4 weeks
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Psychische aandoening
- Neurologische gedragsmanifestaties
- Neurocognitieve stoornissen
- Communicatiestoornissen
- Taalstoornissen
- Spraakstoornissen
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Hartinfarct
- Afasie
- Bewustzijnsstoornissen
Andere studie-ID-nummers
- 345
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .